Skip to main content
NCBI home page
British Medical Journal logoLink to British Medical Journal
. 1971 Jan 30;1(5743):254–257. doi: 10.1136/bmj.1.5743.254

Use of Oxprenolol in Cardiac Arrhythmias Associated with Acute Myocardial Ischaemia

G Sandler, A C Pistevos
PMCID: PMC1794979  PMID: 5100496

Abstract

Oxprenolol, a new beta-receptor blocking drug with intrinsic sympathomimetic activity, was used to treat 63 episodes of cardiac arrhythmia occurring in 43 patients with acute myocardial infarction or myocardial ischaemia. The drug was most effective in abolishing ventricular ectopic beats and supraventricular tachycardia. The best method of administration was by continuous intravenous infusion and the most satisfactory bolus does was 6 mg. The main side effect was hypotension, which occurred in 59% of episodes of arrhythmia that had responded previously to intravenous administration. Oxprenolol was often effective in lignocaine-resistant arrhythmia. The two main advantages of oxprenolol over propranolol are the reduced likelihood of adversely affecting myocardial function and the diminished tendency to produce bronchospasm.

Full text

PDF
254

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bath J. C. Treatment of cardiac arrhythmias in unanesthetized patients. Role of adrenergic beta receptor blockade. Am J Cardiol. 1966 Sep;18(3):415–425. doi: 10.1016/0002-9149(66)90064-6. [DOI] [PubMed] [Google Scholar]
  2. Bender F. Zum Problem der Dosierung bei der Behandlung von Sinustachykardien mit Betarezeptorenblockern. Med Welt. 1968 Nov 9;45:2481–2483. [PubMed] [Google Scholar]
  3. Beumer H. M. Inhalation von Beta-adrenerg blockierenden Substanzen bei Asthmatikern. Med Klin. 1968 Nov 29;63(48):1939–1940. [PubMed] [Google Scholar]
  4. Brunner H., Hedwall P. R., Meier M. Pharmakologische Untersuchungen mit 1-Isopropylamono-3-(o-allyloxyphenoxy)-2-propanol-hydrochlorid, einem adrenergischen beta-Receptorenblocker. Arzneimittelforschung. 1968 Feb;18(2):164–170. [PubMed] [Google Scholar]
  5. Dorph S., Binder C. Evaluation of the hypotensive effect of beta-adrenergic blockade in hypertension. Acta Med Scand. 1969 May;185(5):443–448. doi: 10.1111/j.0954-6820.1969.tb07362.x. [DOI] [PubMed] [Google Scholar]
  6. Epstein S. E., Braunwald E. Beta-adrenergic receptor blocking drugs. Mechanisms of action and clinical applications. N Engl J Med. 1966 Nov 17;275(20):1106–contd. doi: 10.1056/NEJM196611172752006. [DOI] [PubMed] [Google Scholar]
  7. Grandjean T., Rivier J. L. Cardio-circulatory effects of beta-adrenergic blockade in organic heart disease. Comparison between propranolol and CIBA 39,089-Ba. Br Heart J. 1968 Jan;30(1):50–59. doi: 10.1136/hrt.30.1.50. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. HARRISON D. C., GRIFFIN J. R., FIENE T. J. EFFECTS OF BETA-ADRENERGIC BLOCKADE WITH PROPRANOLOL IN PATIENTS WITH ATRIAL ARRHYTHMIAS. N Engl J Med. 1965 Aug 19;273:410–415. doi: 10.1056/NEJM196508192730802. [DOI] [PubMed] [Google Scholar]
  9. Irons G. V., Jr, Ginn W. N., Orgain E. S. Use of a beta adrenergic receptor blocking agent (propranolol) in the treatment of cardiac arrhythmias. Am J Med. 1967 Aug;43(2):161–170. doi: 10.1016/0002-9343(67)90160-x. [DOI] [PubMed] [Google Scholar]
  10. Jewitt D. E., Reid D., Thomas M., Mercer C. J., Valori C., Shillingford J. P. Free noradrenaline and adrenaline excretion in relation to the development of cardiac arrhythmias and heart-failure in patients with acute myocardial infarction. Lancet. 1969 Mar 29;1(7596):635–641. doi: 10.1016/s0140-6736(69)92009-1. [DOI] [PubMed] [Google Scholar]
  11. LUCCHESI B. R. THE EFFECTS OF PRONETHALOL AND ITS DEXTRO ISOMER UPON EXPERIMENTAL CARDIAC ARRHYTHMIAS. J Pharmacol Exp Ther. 1965 Apr;148:94–99. [PubMed] [Google Scholar]
  12. MCNEILL R. S. EFFECT OF A BETA-ADRENERGIC-BLOCKING AGENT, PROPRANOLOL, ON ASTHMATICS. Lancet. 1964 Nov 21;2(7369):1101–1102. doi: 10.1016/s0140-6736(64)92617-0. [DOI] [PubMed] [Google Scholar]
  13. Nayler W. G., Chipperfield D., Lowe T. E. The negative inotropic effect of adrenergic betareceptor blocking drugs on human heart muscle. Cardiovasc Res. 1969 Jan;3(1):30–36. doi: 10.1093/cvr/3.1.30. [DOI] [PubMed] [Google Scholar]
  14. STOCK J. P., DALE N. BETA-ADRENERGIC RECEPTOR BLOCKADE IN CARDIAC ARRHYTHMIAS. Br Med J. 1963 Nov 16;2(5367):1230–1233. doi: 10.1136/bmj.2.5367.1230. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Sandler G., Clayton G. A. Clinical evaluation of practolol, a new cardioselective beta-blocking agent in angina pectoris. Br Med J. 1970 May 16;2(5706):399–402. doi: 10.1136/bmj.2.5706.399. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Stephen S. A. Unwanted effects of propranolol. Am J Cardiol. 1966 Sep;18(3):463–472. doi: 10.1016/0002-9149(66)90071-3. [DOI] [PubMed] [Google Scholar]
  17. Stock J. P. Beta adrenergic blocking drugs in the clinical management of cardiac arrhythmias. Am J Cardiol. 1966 Sep;18(3):444–449. doi: 10.1016/0002-9149(66)90068-3. [DOI] [PubMed] [Google Scholar]
  18. Szekely P., Jackson F., Wynne N. A., Vohra J. K., Batson G. A., Dow W. I. Clinical observations on the use of propranolol in disorders of cardiac rhythm. Am J Cardiol. 1966 Sep;18(3):426–430. doi: 10.1016/0002-9149(66)90065-8. [DOI] [PubMed] [Google Scholar]
  19. Theilen E. O., Wilson W. R. Beta-adrenergic receptor blocking drugs in the treatment of cardiac arrhythmias. Med Clin North Am. 1968 Sep;52(5):1017–1029. [PubMed] [Google Scholar]
  20. Waal H. J. Hypotensive, antiarrhythmic and chronotropic action of Trasicor (Ciba 39089--Ba). N Z Med J. 1968 Mar;67(429):291–295. [PubMed] [Google Scholar]
  21. Williams E. M. Mode of action of beta receptor antagonists on cardiac muscle. Am J Cardiol. 1966 Sep;18(3):399–405. doi: 10.1016/0002-9149(66)90062-2. [DOI] [PubMed] [Google Scholar]
  22. Wilson D. F., Watson O. F., Peel J. S., Langley R. B., Turner A. S. Some haemodynamic effects of trasicor (Ciba 39,089-Ba). N Z Med J. 1968 Sep;68(436):145–149. [PubMed] [Google Scholar]

Articles from British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES